MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy

Abstract

The CD133 antigen is a marker of radio- and chemo-resistant stem cell populations in glioblastoma (GBM). The O6-methylguanine DNA methyltransferase (MGMT) enzyme is related with temozolomide (TMZ) resistance. Our propose is to analyze the prognostic significance of the CD133 antigen and promoter methylation and protein expression of MGMT in a homogenous… (More)
DOI: 10.1186/1479-5876-10-250

Topics

9 Figures and Tables

Cite this paper

@inproceedings{Melguizo2012MGMTPM, title={MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy}, author={Consolaci{\'o}n Melguizo and Jose Prados and Beatriz Gonz{\'a}lez and Raul Ortiz and Angel Concha Concha and Pablo {\'A}lvarez and Roberto Madeddu and Gloria Perazzoli and Jaime Antonio Oliver and Rodrigo Lopez and Fernando Rodr{\'i}guez-Serrano and A. Ar{\'a}nega}, booktitle={Journal of Translational Medicine}, year={2012} }